Moreover, treating zinc-deficient cells with imatinib, the tyrosine kinase inhibitor, succeeded in reversing the effect of zinc-deficiency-induced EGFR phosphorylation and also reversed the increased PBMC death rate. This evidence concerns the gene EGFR and Zinc deficiency.